Akeso Opens U.S. Phase II Trial for PD-1/CTLA-4 Bispecific
HONG KONG, July 14, 2026 Akeso, Inc. has announced the launch of a Phase II clinical trial in the...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
HONG KONG, July 14, 2026 Akeso, Inc. has announced the launch of a Phase II clinical trial in the...
CHENGDU, China, July 14, 2026 HitGen Inc. has announced that its partner BioAge Labs has dosed the first participant...
SAN DIEGO, Calif., July 14, 2026 Atrium Therapeutics has achieved an important regulatory milestone after the U.S. Food and...
